Samjin Pharmaceuticals Co., Ltd.
005500.KSFinancial Statements
Income Statement (Annual)
Amounts in millions
2024
12/31/2024
Revenue
231
Cost of Revenue
135
Gross Profit
97
Gross Margin
41.8%
Operating Income
24
Operating Margin
10.3%
Net Income
29
Net Margin
12.7%
EPS (Basic)
$2.00
EPS (Diluted)
$2.00
EBITDA
49
EBITDA Margin
21.4%
2023
12/31/2023
Revenue
219
Cost of Revenue
110
Gross Profit
109
Gross Margin
49.9%
Operating Income
15
Operating Margin
7.0%
Net Income
14
Net Margin
6.5%
EPS (Basic)
$1.00
EPS (Diluted)
$1.00
EBITDA
27
EBITDA Margin
12.5%
2022
12/31/2022
Revenue
206
Cost of Revenue
117
Gross Profit
88
Gross Margin
43.0%
Operating Income
17
Operating Margin
8.5%
Net Income
16
Net Margin
8.0%
EPS (Basic)
$1.00
EPS (Diluted)
$1.00
EBITDA
28
EBITDA Margin
13.4%
2021
12/31/2021
Revenue
188
Cost of Revenue
99
Gross Profit
88
Gross Margin
47.1%
Operating Income
25
Operating Margin
13.6%
Net Income
21
Net Margin
11.4%
EPS (Basic)
$2.00
EPS (Diluted)
$2.00
EBITDA
31
EBITDA Margin
16.5%
2020
12/31/2020
Revenue
176
Cost of Revenue
93
Gross Profit
83
Gross Margin
47.0%
Operating Income
24
Operating Margin
13.7%
Net Income
21
Net Margin
11.9%
EPS (Basic)
$2.00
EPS (Diluted)
$2.00
EBITDA
30
EBITDA Margin
16.7%